Conservative talk radio host and Republican party supporter Rush Limbaugh has died. He was 70 years old.
Ghana began its coronavirus vaccination drive on Tuesday with 600,000 AstraZeneca doses it received from the global COVAX vaccine-sharing facility aimed at providing shots to developing nations to help combat the COVID-19 pandemic. People lined up for shots outside the regional hospital in the capital, Accra, for a first phase of vaccinations which will prioritise frontline health workers and others at high risk. While western nations have secured millions of doses and launched mass vaccination drives, most poorer countries do not yet have access to any, raising concerns about equitable distribution of vaccines to fight the pandemic.
Both tech giants face fierce regulatory headwinds, but one of these stocks is clearly a stronger long-term investment.
Concert will present a corporate overview at the H.C. Wainwright and Oppenheimer virtual conferences in March.
$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by Year End 2021 OTL-200 U.S. Filing Strategy for Metachromatic Leukodystrophy (MLD) Expected by Mid-2021 R&D Organizational Leadership Changes Announced BOSTON and LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today reported financial results for the year ended December 31, 2020, as well as recent accomplishments, 2021 strategic priorities and upcoming milestones, and related organizational leadership updates. Frank Thomas, president and chief operating officer said, “It is gratifying to witness the positive momentum Orchard has already established in early 2021 driven by solid execution. Our compelling data in neurodegenerative disorders at the WORLDSymposium and successful completion of the $150 million financing exemplify this recent progress and showcase a growing appreciation for the potential of HSC gene therapy. We look forward to continuing our work in the year ahead and delivering further benefit for patients and our shareholders." Recent Accomplishments February 2021 Executed a $150 million private investment in public equity (PIPE) financing at a price of $6.22 per share with several existing and new investors with expertise in healthcare, including RA Capital Management, Avidity Partners, Casdin Capital, Farallon Capital, and Surveyor Capital (a Citadel company), among others. The link to the full release is available here.Presented data from multiple neurometabolic programs at the 2021 WORLDSymposium. The link to the full release is available here. Interim data for OTL-203 showing positive clinical results in multiple disease manifestations of MPS-IH was highlighted. All eight patients treated with OTL-203 showed stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment. Treatment with OTL-203 has been generally well-tolerated with a safety profile consistent with the selected conditioning regimen.An oral presentation featuring supportive biomarker data from the first three patients in the ongoing OTL-201 POC study for mucopolysaccharidosis type IIIA (MPS-IIIA, or Sanfilippo syndrome) was also featured. The treatment has been generally well-tolerated in the first three patients with no treatment-related serious adverse events (SAEs), and all transplant-related SAEs and adverse events have resolved. January 2021 Appointed Braden Parker as chief commercial officer. Mr. Parker most recently served as Orchard’s senior vice president and general manager for North America and has more than 20 years of experience in the healthcare industry, including commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s U.S. product launch in Duchenne muscular dystrophy and oversaw strategic planning for the gene therapy business.Received Regenerative Medicine Advanced Therapy (RMAT) designation for OTL-200 from the U.S. Food and Drug Administration (FDA) for early-onset MLD. This designation has the potential to enhance regulatory interactions in the U.S. and open an expedited path to a biologics license application (BLA) filing.Secured partnerships with two leading regional specialty pharmaceutical companies to broaden access to Libmeldy (OTL-200) for eligible patients with MLD in the Middle East & Turkey. 2021 Corporate Priorities and Upcoming Milestones Orchard previously outlined the following key corporate objectives and upcoming expected milestones: Build a successful commercial business in hematopoietic stem cell (HSC) gene therapy Launch Libmeldy (OTL-200) for the treatment of eligible patients with early-onset MLD in Europe in the first half of 2021Complete additional interactions with the FDA by mid-2021 to determine the path to a BLA filing for OTL-200File an Marketing Authorization Application (MAA) for OTL-103 in Wiskott-Aldrich syndrome (WAS) with the European Medicines Agency by year-end 2021; followed by a BLA filing in the U.S. in 2022 Continue to lead the development of gene therapies for neurodegenerative disorders by advancing two POC programs in MPS-IH and MPS-IIIA Initiate a registrational trial for OTL-203 for MPS-IH by year-end 2021Complete enrollment in the five-patient POC trial for OTL-201 for MPS-IIIAPresent additional clinical data from the OTL-203 and OTL-201 POC trials Investigate the potential of HSC gene therapy in larger indications Announce new preclinical data from research programs in frontotemporal dementia with progranulin mutations (GRN-FTD) and Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD) in the second half of 2021 Organizational Leadership Updates Given the progress on key development programs, Anne Dupraz has been appointed to the expanded role of chief development officer. In addition to overseeing the company’s regulatory strategy, Ms. Dupraz will lead product development with the goal of ensuring a seamless approach to moving Orchard’s programs through to potential regulatory approval. Ms. Dupraz possesses more than 20 years of experience in the clinical and regulatory fields and has deep expertise in advanced therapies, having been involved in more than 50 different tissue, cell and gene-based therapy development programs in her career. Ran Zheng, chief technical officer, and Andrea Spezzi, chief medical officer, are stepping down from their respective leadership positions with Orchard to pursue other opportunities. Orchard has initiated a global search for permanent replacements for both of these roles. Fourth Quarter 2020 Financial Results Research and development expenses were $22.6 million for the three months ended December 31, 2020, compared to $30.9 million in the same period in 2019. R&D expenses include the costs of clinical trials and preclinical work on the company’s portfolio of investigational gene therapies, as well as costs related to regulatory, manufacturing, license fees and milestone payments under the company’s agreements with third parties, and personnel costs to support these activities. The company expects R&D expenses to grow slightly in the upcoming periods as the company continues to advance its programs through later stages of development. Selling, general and administrative expenses were $16.2 million for the three months ended December 31, 2020, compared to $18.5 million in the same period in 2019. The decrease was primarily due to realization of savings associated with an updated strategy and corporate restructuring announced in May 2020. Net loss attributable to ordinary shareholders was $33.6 million for the three months ended December 31, 2020, compared to $45.4 million in the same period in 2019. The decline in net loss as compared to the prior year was primarily due to savings realized in our operating expenses as a result of the company’s updated strategy and corporate restructuring. The company had 98.3 million ordinary shares outstanding as of December 31, 2020. Thomas continued, "Our burn rate has declined from prior periods as we see the positive impact of our May 2020 corporate restructuring take hold, providing a longer runway and greater financial flexibility, aided by our recent financing. We are investing to support execution for the highest value programs in our portfolio while also dedicating capital to our longer-term strategy to expand into larger indications. Cash, cash equivalents and investments as of December 31, 2020, were $191.9 million compared to $325.0 million as of December 31, 2019, with the decrease primarily driven by cash used to fund operations in 2020. In the fourth quarter of 2020, the cash used to fund operations was approximately $12.0 million after the receipt of approximately $19.2 million from R&D tax credit refunds related to 2019 qualifying activities under the tax code in the UK. The company expects that its cash, cash equivalents and investments as of December 31, 2020, along with gross proceeds of $150.0 million from the February 2021 private placement, will support its currently anticipated operating expenses and capital expenditure requirements into the first half of 2023. This cash runway excludes the $50 million available under the company’s credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers granted by the FDA following future potential U.S. approvals. About Libmeldy / OTL-200Libmeldy (autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase-A (ARSA) gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD.The most common adverse reaction attributed to treatment with Libmeldy was the occurrence of anti-ARSA antibodies. In addition to the risks associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability.For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website.Libmeldy is not approved outside of the European Union, UK, Iceland, Liechtenstein and Norway. OTL-200 is an investigational therapy in the US. Libmeldy was developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.About Orchard Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn. Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward-Looking Statements This press release contains certain forward-looking statements about Orchard’s strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchard’s business strategy and goals, including its plans and expectations for the commercialization of Libmeldy, the therapeutic potential of Libmeldy (OTL-200) and Orchard’s product candidates, including the product candidates referred to in this release, Orchard’s expectations regarding its ongoing preclinical and clinical trials, including the timing of enrollment for clinical trials and release of additional preclinical and clinical data, the likelihood that data from clinical trials will be positive and support further clinical development and regulatory approval of Orchard's product candidates, and Orchard’s financial condition and cash runway into the first half of 2023. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchard’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from clinical trials of Libmeldy will not continue or be repeated in our ongoing or planned clinical trials of Libmeldy, will be insufficient to support regulatory submissions or marketing approval in the US or to maintain marketing approval in the EU, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchard’s product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchard’s ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchard’s product candidates; the delay of any of Orchard’s regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchard’s product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchard’s ability to commercialize its product candidates, if approved, or Libmeldy, including the risk that Orchard may not secure adequate pricing or reimbursement to support continued development or commercialization of Libmeldy; the risk that the market opportunity for Libmeldy, or any of Orchard’s product candidates, may be lower than estimated; and the severity of the impact of the COVID-19 pandemic on Orchard’s business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchard’s quarterly report on Form 10-Q for the quarter ended September 30, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchard’s views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Consolidated Statements of Operations Data(In thousands, except share and per share data)(Unaudited) Three months ended December 31, 2020 2019 Product sales, net$— $595 Costs and operating expenses: Cost of product sales — 191 Research and development 22,648 30,899 Selling, general and administrative 16,226 18,531 Total costs and operating expenses 38,874 49,621 Loss from operations (38,874) (49,026)Other income (expense): Interest income 279 1,843 Interest expense (575) (633)Other income, net 5,635 2,533 Total other income, net 5,339 3,743 Net loss before income tax (33,535) (45,283)Income tax expense (85) (133)Net loss attributable to ordinary shareholders$(33,620) $(45,416) Consolidated Balance Sheet Data(in thousands)(Unaudited) December 31,December 31, 2020 2019 Assets Current assets: Cash and cash equivalents $55,135$19,053 Marketable securities 136,813 305,937 Trade receivables 878 1,442 Prepaid expenses and other current assets 13,365 8,530 Research and development tax credit receivable, current 17,344 14,934 Total current assets 223,535 349,896 Non-current assets: Operating lease right-of-use assets 29,815 19,415 Property and equipment, net 4,781 7,596 Research and development tax credit receivable — 13,710 Other long-term assets 22,806 8,664 Total non-current assets 57,402 49,385 Total assets $280,937$399,281 Liabilities and shareholders' equity Current liabilities: Accounts payable $8,823$11,984 Accrued expenses and other current liabilities 28,943 37,980 Operating lease liabilities 8,934 5,892 Notes payable, current 4,861 — Total current liabilities 51,561 55,856 Notes payable, long-term 20,204 24,699 Operating lease liabilities, non-current 24,168 15,320 Other long-term liabilities 6,570 4,213 Total liabilities 102,503 100,088 Shareholders’ equity: 178,434 299,193 Total liabilities and shareholders’ equity $280,937$399,281 Contacts InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com MediaChristine HarrisonVice President, Corporate Affairs+1 202-415-0137media@orchard-tx.com
CALGARY, Alberta, March 02, 2021 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to provide the following information concerning its February 2021 natural gas sales and drilling program. Gas Sales Averaged 187 MMscfpd for February 2021 Realized contractual natural gas sales (which are gas produced, delivered, and paid for) were 187 million standard cubic feet per day (“MMscfpd”) for February 2021, a 6% increase from average gas sales of 177 MMscfpd for the month of January 2021. Flauta 1 and Oboe 2 The Flauta 1 exploration well which completed drilling in February 2021 did not encounter commercial gas and has been plugged and abandoned. The Oboe 2 development well has been completed as a successful gas producer and is being tied into the Jobo gas processing facility. The rigs are currently being mobilized to drill the Cañahuate 4 development well and the Milano 1 exploration well, both of which are anticipated to spud the second week of March 2021. Each will take approximately 5 weeks to drill and test. About Canacol Canacol is a natural gas exploration and production company with operations focused in Colombia. The Corporation's common stock trades on the Toronto Stock Exchange, the OTCQX in the United States of America, and the Colombia Stock Exchange under ticker symbol CNE, CNNEF, and CNE.C, respectively. This press release contains certain forward-looking statements within the meaning of applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur, including without limitation statements relating to estimated production rates from the Corporation's properties and intended work programs and associated timelines. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation cannot assure that actual results will be consistent with these forward-looking statements. They are made as of the date hereof and are subject to change and the Corporation assumes no obligation to revise or update them to reflect new circumstances, except as required by law. Prospective investors should not place undue reliance on forward looking statements. These factors include the inherent risks involved in the exploration for and development of crude oil and natural gas properties, the uncertainties involved in interpreting drilling results and other geological and geophysical data, fluctuating energy prices, the possibility of cost overruns or unanticipated costs or delays and other uncertainties associated with the oil and gas industry. Other risk factors could include risks associated with negotiating with foreign governments as well as country risk associated with conducting international activities, and other factors, many of which are beyond the control of the Corporation. Realized contractual gas sales is defined as gas produced and sold plus gas revenues received from nominated take or pay contracts. CONTACT: For more information please contact: Investor Relations South America: +571.621.1747 IR-SA@canacolenergy.com Global: +1.403.561.1648 IR-GLOBAL@canacolenergy.com http://www.canacolenergy.com
Piraeus, Greece, March 02, 2021 (GLOBE NEWSWIRE) -- GasLog Partners LP (“GasLog Partners” or the “Partnership”) (NYSE: GLOP) announced today that its Annual Report on Form 20-F for the fiscal year ended December 31, 2020 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission and can be accessed on the Partnership’s website, http://www.gaslogmlp.com, in the “Investor Relations” section under “SEC Filings”. Unitholders may also request a hard copy of the Annual Report, which includes the Partnership’s complete 2020 audited financial statements, free of charge by contacting: Email: ir@gaslogmlp.com Phone: +1-212-223-0643 About GasLog Partners GasLog Partners is a growth-oriented owner, operator and acquirer of LNG carriers. The Partnership’s fleet consists of 15 LNG carriers with an average carrying capacity of approximately 158,000 cbm. GasLog Partners is a publicly traded master limited partnership (NYSE: GLOP) but has elected to be treated as a C corporation for U.S. income tax purposes and therefore its investors receive an Internal Revenue Service Form 1099 with respect to any distributions declared and received. The Partnership’s principal executive offices are located at 69 Akti Miaouli, 18537, Piraeus, Greece. Visit GasLog Partners’ website at http://www.gaslogmlp.com. Contacts:Joseph NelsonHead of Investor RelationsPhone: +1-212-223-0643 Email: ir@gaslogmlp.com
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting format.
Sixth Series Designed to Target Private Credit Investments around the WorldBALA CYNWYD, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Leading private markets investment management firm Hamilton Lane (NASDAQ: HLNE) today announced the final closing of Hamilton Lane Strategic Opportunities Fund VI (“the Fund”). The Fund represents nearly $900 million in commitments from a wide range of global LPs. The Fund is focused on making credit-oriented investments striving for consistent cash yield, shorter duration and attractive risk-adjusted returns. Consistent with previous vintage vehicles, the Fund is comprised of a diverse set of institutions, including returning as well as new investors from Asia, the Middle East, Europe and North and South America. Drew Schardt, Head of Direct Credit at Hamilton Lane, commented: “The private credit landscape continues to evolve, marked by growing LP interest driven generally by the opportunity for risk mitigation, yield and return characteristics offered within the context of a broader private markets portfolio.” “This latest close is a continuation of our proven strategy and platform, and of our ability to bring to bear more than two decades of experience, differentiated deal flow and strong relationships to consistently access unique private credit-oriented opportunities on a global level,” he said. Jackie Rantanen, Head of Product Management at Hamilton Lane, said: “We’re thankful to our strong global client base for supporting what is our sixth successful fundraise for the Strategic Opportunities Series. We intentionally structure this Series as a unique and appealing solution for investors seeking a high level of flexibility and optionality, while benefiting from Hamilton Lane’s extensive global platform and opportunity set.” Hamilton Lane has long been an active investor in targeted strategies, including credit-oriented direct investments and co-investments. While this vehicle represents the sixth of its kind, it is an extension of Hamilton Lane’s broader credit platform, which the firm has been building for over 20 years and which represents more than $40 billion in assets under management and supervision as of September 30, 2020. About Hamilton LaneHamilton Lane (NASDAQ: HLNE) is a leading private markets investment management firm providing innovative solutions to sophisticated investors around the world. Dedicated exclusively to private markets investing for 29 years, the firm currently employs more than 440 professionals operating in offices throughout North America, Europe, Asia Pacific and the Middle East. Hamilton Lane has approximately $657 billion in assets under management and supervision, composed of approximately $76 billion in discretionary assets and approximately $581 billion in advisory assets, as of December 31, 2020. Hamilton Lane specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors and geographies. For more information, please visit www.hamiltonlane.com or follow Hamilton Lane on Twitter: @hamilton_lane. Forward-Looking Statements Some of the statements in this release may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Words such as “will,” “expect,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan” and similar expressions are intended to identify these forward-looking statements. Forward-looking statements discuss management’s current expectations and projections relating to our financial position, results of operations, plans, objectives, future performance and business. All forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different, including risks relating to: our ability to manage growth, fund performance, risk, changes in our regulatory environment and tax status; market conditions generally; our ability to access suitable investment opportunities for our clients; our ability to maintain our fee structure; our ability to attract and retain key employees; our ability to manage our obligations under our debt agreements; defaults by clients and third-party investors on their obligations to fund commitments; our ability to comply with investment guidelines set by our clients; our ability to consummate planned acquisitions and successfully integrate the acquired businesses with ours; our ability to manage risks associated with pursuing new lines of business; our ability to manage the effects of events outside of our control; and our ability to receive distributions from Hamilton Lane Advisors, L.L.C. to fund our payment of dividends, taxes and other expenses. The foregoing list of factors is not exhaustive. For more information regarding these risks and uncertainties as well as additional risks that we face, you should refer to the “Risk Factors” detailed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2020 and in our subsequent reports filed from time to time with the Securities and Exchange Commission. The forward-looking statements included in this release are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information or future events, except as otherwise required by law. Media ContactKate McGannkmcgann@hamiltonlane.com+1 240 888 4078 Investor ContactJohn Ohjoh@hamiltonlane.com +1 610 617 6026
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021. The presentation will be made available for on-demand listening beginning Tuesday, March 9th at 7:00 a.m. Eastern Time and may be accessed on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The recording will be made available for a period of 30 days following the event. About Baudax Bio Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com. CONTACT: Investor Relations Contact:Argot PartnersSam Martin / Claudia Styslinger(212) 600-1902baudaxbio@argotpartners.com Baudax Bio, Inc.Ryan D. Lake(484) 395-2436rlake@baudaxbio.com Media Contact:Argot PartnersDavid Rosen(212) 600-1902david.rosen@argotpartners.com
Mt. Jamie North Gold Project Geology and Highlights TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Stone Gold Inc. (TSX-V: STG) ("Stone Gold" or the "Company") is pleased to announce that it has signed a diamond drilling contract with Rodren Drilling Ltd. for the Mt. Jamie North property located in Red Lake, Ontario. The preliminary drill program is for a minimum of 900 metres NQ drilling and is expected to be completed by end of March 2021. Stone Gold President and CEO John Timmons states, “We are excited to have the opportunity to drill the untested Mt. Jamie North Property located in Red Lake. All the targets for this program are on strike with the historical Mt. Jamie Mine and West Red Lakes Rowan Mine Property that has 1.1 million inferred ounces of gold. We hope to further the evidence of gold mineralization along the western trend of the Red Lake mining camp.” To view the accompanying “Mt. Jamie North Gold Project – Geology and Highlights” photo, please visit:https://www.globenewswire.com/NewsRoom/AttachmentNg/f0c49b52-bcfa-4ca1-9d1b-9a1eb0dcc536 For further information, please contact:Mr. John TimmonsPresident & CEOStone Gold Inc.Cellular (416) 931 2243Email: jtimmons@stonegold.caWeb: www.stonegold.ca Stone Gold Inc. is engaged in the acquisition, exploration and evaluation of properties for the mining of precious and base metals. Caution Regarding Forward-Looking Information This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Stone Gold. Forward-looking statements include estimates and statements that describe Stone Gold's future plans, objectives or goals, including words to the effect that Stone Gold or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Stone Gold, Stone Gold provides no assurance that actual results will meet management's expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, Stone Gold's objectives, goals or future plans, statements, details of the exploration results, potential mineralization, Stone Gold's portfolio, treasury, management team and enhanced capital markets profile, the timing of the Transaction, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure or inability to complete the Transaction on the terms as announced or at all, regulatory approval processes, failure to identify mineral resources, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in Stone Gold's public documents filed on SEDAR. Although Stone Gold believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Stone Gold disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
DELRAY BEACH, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and Chief Executive Officer, will participate in a “fireside chat” with Yi Chen, Managing Director, Equity Research at H.C. Wainwright, during the H.C. Wainwright Global Life Sciences Conference being held virtually March 9-11, 2021. During the fireside chat, Mr. Sapirstein will provide an overview of AzurRx’ business and clinical development programs and discuss anticipated 2021 milestones. Additionally, during the conference, Mr. Sapirstein and members of the AzurRx management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Details of the fireside chat are as follows: Event: H.C. Wainwright Global Life Sciences Conference Date: Tuesday, March 9, 2021 Time: 7:00 a.m. ET Registration: https://hcwevents.com/globalconference/ About AzurRx BioPharma, Inc.AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI clinical programs. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida. with clinical operations in Hayward, California. For more information visit www.azurrx.com. Forward-Looking StatementsThis press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead, represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial such as the interim results presented will be indicative of the final results of the trial; and the Company’s success in raising additional financing to support its operations. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results, including those related to the clinical development of MS1819, the results of its clinical trials, and the impact of the coronavirus (COVID-19) pandemic on the Company’s operations and current and planned clinical trials, including, but not limited to delays in clinical trial recruitment and participation are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware. For more information: AzurRx BioPharma, Inc.1615 South Congress AvenueSuite 103Delray Beach, Florida 33445Phone: (646) 699-7855info@azurrx.com Investor Relations contact: LifeSci Advisors, LLC. Hans Vitzthum, Managing Director 1 International Place, Suite 1480 Boston, MA 02110 Phone: (617) 430-7578 hans@lifesciadvisors.com Media contact: Tiberend Strategic Advisors, Inc.Johanna Bennett/Ingrid Mezo(212) 375-2665/(646) 604-5150jbennett@tiberend.com/imezo@tiberend.com
Old Dominion Freight Line, Inc. (Nasdaq: ODFL) today reported certain less-than-truckload ("LTL") operating metrics for February 2021. Revenue per day increased 9.2% as compared to February 2020 due to a 5.9% increase in LTL tons per day and an increase in LTL revenue per hundredweight. The change in LTL tons per day was attributable to a 4.1% increase in LTL weight per shipment and a 1.8% increase in LTL shipments per day. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight excluding fuel surcharges increased 2.7% and 3.8%, respectively, as compared to the same period last year.
Together the companies will complete the hydrogen value chain for aviationLATHAM, N.Y. and LOS ANGELES, March 02, 2021 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a leading provider of turnkey hydrogen solutions building the global green hydrogen economy, today announced an expansion of the relationship with Universal Hydrogen Co., a pioneer in hydrogen aviation. The companies previously announced a partnership to develop a fuel cell-based hydrogen powertrain for regional aircraft. The recent minority investment by Plug Power will enable Universal Hydrogen to complete the construction of a subscale aircraft powertrain by Q2 2021. In addition to this strategic investment, the companies further agreed to a global offtake relationship that will see green hydrogen become cost-competitive with jet fuel by 2025. Plug Power is an innovator and a leader in the green hydrogen economy, with over 40,000 fuel cell systems, 150 fueling stations deployed globally, and dispensing more than 40 tons of hydrogen daily. The company also has a comprehensive solution for generating green hydrogen including its leading electrolyzer technology and liquefaction capabilities. Plug Power recently announced its plans to build five regional green hydrogen facilities in the United States. The combination of low-cost renewables, strong capital position, and in house electrolyzer and liquefaction technology all uniquely position Plug Power to build out this green hydrogen network. “When you think about renewables at 4 cents per kW-hr, it’s clear that green hydrogen can be produced at prices equivalent to or below fossil fuel based hydrogen in the near term,” said Andy Marsh, Chief Executive Officer, Plug Power. “Universal Hydrogen’s approach is a pragmatic, near-term plan to bring green hydrogen to one of the hardest to decarbonize sectors—air travel.” Following a successful ground demonstration, the teams will retrofit the hydrogen fuel cell powertrain into a 40-60 passenger regional aircraft, with first experimental flights slated for 2023 and entry into revenue service in 2025. Plug Power’s strategic investment is the company’s latest commitment to the aerospace industry following the completion of its June 2019 acquisition of EnergyOr, a company that specialized in advanced lightweight and compact PEM hydrogen fuel cell (HFC) systems for robotics, small-scale material handling, and aerospace applications. “This global supply agreement for green hydrogen will enable us to deliver modular fuel capsules to airline operators at a price that gives them equivalent unit economics to a conventional jet fuel-powered regional aircraft in 2025, with additional operating cost savings as the cost of hydrogen continues to decrease,” said Paul Eremenko, Chief Executive Officer, Universal Hydrogen. “The economics just make sense, and our order book speaks for itself. We're thrilled to have Plug Power as a strategic partner and now an investor as we make carbon-free flight a near-term reality.” Today’s announcements advance Universal Hydrogen’s business model of using modular capsules to distribute hydrogen via the existing freight network directly to the aircraft, with no new infrastructure needed for transport or airport operations which can accelerate adoption of the new technology. About Plug PowerPlug Power is building the hydrogen economy as the leading provider of comprehensive hydrogen fuel cell (HFC) turnkey solutions. The company’s innovative technology powers electric motors with hydrogen fuel cells amid an ongoing paradigm shift in the power, energy, and transportation industries to address climate change and energy security, while providing efficiency gains and meeting sustainability goals. Plug Power created the first commercially viable market for hydrogen fuel cell (HFC) technology. As a result, the company has deployed over 40,000 fuel cell systems for e-mobility, more than anyone else in the world, and has become the largest buyer of liquid hydrogen, having built and operated a hydrogen highway across North America. Plug Power delivers a significant value proposition to end-customers, including meaningful environmental benefits, efficiency gains, fast fueling, and lower operational costs. Plug Power’s vertically-integrated GenKey solution ties together all critical elements to power, fuel, and provide service to customers such as Amazon, BMW, The Southern Company, Carrefour, and Walmart. The company is now leveraging its know-how, modular product architecture and foundational customers to rapidly expand into other key markets including zero-emission on-road vehicles, robotics, and data centers. About Universal HydrogenUniversal Hydrogen is dedicated to making hydrogen aviation a near-term reality. The company is building a hydrogen ecosystem for aviation through strategic partnerships and new technologies for hydrogen distribution and propulsion. Founded in 2020 by former Airbus CTO Paul Eremenko, together with eminent academic and entrepreneur John-Paul Clarke, aviation and energy attorney Jon Gordon, and Silicon Valley veteran Jason Chua, Universal Hydrogen takes a flexible, scalable, and capital-light approach to hydrogen logistics by transporting it in lightweight, aviation-certified modular capsules over the existing intermodal containerized freight network from green production sites to airports around the world. To accelerate market adoption, Universal Hydrogen is also developing a conversion kit to retrofit existing regional airplanes with a hydrogen-electric powertrain compatible with the modular capsule technology. For more information, go to hydrogen.aero. Safe Harbor StatementThis communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc.("PLUG"), including but not limited to statements about PLUG's expectations regarding its multi-year investment and growth , PLUG’s clean hydrogen technology and fuel cell solutions playing a critical role in achieving climate and decarbonization goals, deepening of relationships with key stakeholders, and acceleration of demand and adoption of hydrogen technology . You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times that, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of PLUG in general, see PLUG’s public filings with the Securities and Exchange Commission, including the “Risk Factors” section of PLUG’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made as of the date hereof, and PLUG undertakes no obligation to update such statements as a result of new information. Plug Power Media Contact Ian MartoranaThe Bulleit Group (415) 237-3681plugpowerpr@bulleitgroup.com Universal Hydrogen Media Contact Kate Gundry Pluck PR (617) 797-5174 Uh2@pluckpr.com SOURCE: PLUG POWER
Decentralized media platform Discussions.app is developing its infrastructure and reputation system on Telos, completing a full migration from EOSLONDON, March 02, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire) - Telos (www.telos.net), one of the most active blockchain platforms in the world according to Blocktivity and CryptoDiffer, today announced that decentralized media platform Discussions.app will be using Telos as the primary infrastructure and development platform for its Aura, a decentralized reputation system aimed to provide DApps a sense of the value of their interactions by providing an intuitive and direct way to quantify the “realness” of a user. Discussions.app will be migrating all of its core operations and content from EOS, where Discussions.app had been one of that blockchain platform’s more popular DApps. “In the time we’ve spent working with Telos, we couldn’t ask for a more capable or engaged partner. What we are looking to do now is a full migration to Telos. This will better serve Discussions.app and our users by focusing on a well-governed, and well-operated blockchain with a clear vision of the future.” said Jacques Xu, Co-Founder of Discussions.app. “We will continue to support and honor EOS tokens on our platform, but will move our core smart-contracts on to Telos and be prepared to tap into the technical advancements to come on Telos.” Discussions.app is a decentralized, Reddit-inspired social aggregation platform that empowers users to control their own digital identity and connections while sharing content from anywhere on the web, regardless of unilateral actions by other host platforms. Integral to Discussions.app is its new reputation system, to be built on Telos, which simplifies the process for interacting with blockchain technology and provides developers with critical data about its users.“We are not only technically in sync with Discussions.app, but philosophically in sync as well. We are honored and excited that the Discussions.app team feels our platform has everything it needs to take the development of technologies like Aura to the next level,” said Douglas Horn, Telos Chief Architect. “We look forward to joining with other apps and platforms like Discussions.app that want and need every resource possible to build the future of the decentralized web.” In addition to speed, capacity and zero transaction fees, Telos has many advantages over other platforms that make it the most advanced blockchain software for smart contracts and decentralized applications. Telos’ governance structure gives developers and community members control of the platform to a greater extent than any comparable blockchain, rather than a centralized entity, small groups, or individual whaled and these governance functions are made available to any Telos developers to use in their own DApps via the Telos Decide governance engine. The Telos network currently supports 10,000 transactions per second (TPS) with zero transaction fees, compared to Ethereum’s 14 TPS with fees. The full Telos Technical Roadmap 2021 can be viewed here. About Telos Telos is a high-capacity network and one of the most active blockchain platforms in the world according to Blocktivity. Telos features a robust, third-generation blockchain governance system including advanced voting features and smart contracts that can be fully configured to meet the needs of any developer. Created by developers for developers, Telos extends its state-of-the-art blockchain and governance features to all DApps on its platform, delivering the best user experience in the marketplace. Telos also supports the blockchain ecosystem by serving as an incubator and accelerator for decentralized applications. For more information, please visit www.telos.net. About Discussions.appDiscussions.app is a decentralized media platform that empowers users to control their own digital identity and connections while sharing content from anywhere on the web. The network is powered by the ATMOS token. To learn more, please visit discussions.app. CONTACT: MEDIA CONTACT: Transform Group, telos@transformgroup.com
New York, March 02, 2021 (GLOBE NEWSWIRE) -- London, UK – 2 March 2021 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year ended 31 December 2020, and provide an update on recent business developments, on 9 March 2021. The management team will host a conference call at 1:00pm GMT (8.00am ET) on 9 March. The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 5558345. The call will also be webcast on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days. -Ends- About COMPASS PathwaysCOMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com Contacts: COMPASS Pathways Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024 Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401-290-7324 Attachment COMPASS Call Date Announcement 3-2-21 final
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021 to report its fourth quarter and full year 2020 financial results and discuss business highlights. To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 3094547. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call. About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on SINTAX with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer. Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas. For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn. ContactJessica Cotrone, 978-760-5622jcotrone@evelobio.com
Humanigen awarded two patents, expanding their anti-GM-CSF patent portfolio.
KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered KT-474 in healthy volunteers, as well as in patients with atopic dermatitis or hidradenitis suppurativa WATERTOWN, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company recently initiated dosing in the single ascending dose (SAD) portion of the Phase 1 clinical trial evaluating KT-474 in adult healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa. KT-474 is a potential first-in-class, highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis and potentially other indications. “We are excited to initiate dosing in the SAD portion of the Phase 1 trial of KT-474, marking the first time that a heterobifunctional small molecule degrader has ever been administered to healthy volunteers,” said Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics. “Atopic dermatitis, hidradenitis suppurativa and rheumatoid arthritis collectively impact millions of people in the U.S. alone, and we believe our novel approach of degrading IRAK4 with KT-474 offers the potential to improve outcomes over current treatment options. We look forward to our next milestone of establishing safety, on-target pharmacology, and mechanistic proof-of-concept with KT-474 in healthy volunteers later this year.” The first-in-human Phase 1 trial is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered KT-474 in adult healthy volunteers and patients with atopic dermatitis or hidradenitis suppurativa. Additional information on this clinical trial can be found on www.clinicaltrials.gov. “KT-474 is the first heterobifunctional protein degrader candidate to advance into the clinic for immune-inflammatory conditions, representing a significant achievement for Kymera and an important milestone for the whole field of targeted protein degradation,” said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “I am proud of the progress that our R&D organization has made to advance our first program into the clinic in only four years, and we are looking forward to the initiation of our IRAKIMiD and STAT3 Phase 1 oncology trials in 2021, setting up a transformational year for Kymera.” About IRAK4 and KT-474 IRAK4 is a key protein involved in inflammation mediated by the activation of TLRs and IL-1Rs. Aberrant activation of these pathways is the underlying cause of multiple immune-inflammatory conditions. KT-474 is designed to block TLR/IL-1R-mediated inflammation more broadly compared to monoclonal antibodies targeting single cytokines and enable pathway inhibition that is superior to IRAK4 kinase inhibitors by abolishing both the kinase and scaffolding functions of IRAK4. Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immuno-oncology fields. About Pegasus™Pegasus™ is Kymera Therapeutics’ proprietary protein degradation platform, created by its team of experienced drug hunters to improve the effectiveness of targeted protein degradation and generate a pipeline of novel therapeutics for previously undruggable diseases. The platform consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities, and degradation tools. About Kymera TherapeuticsKymera Therapeutics is a biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, which each address high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the IRAK4, IRAKIMiD and STAT3 degrader programs; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company’s planned interactions with regulatory authorities, including the resolution of the current partial clinical hold for KT-474; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the period ended September 30, 2020, filed on November 5, 2020, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor Contact:Paul CoxVP, Investor Relations and Communicationspcox@kymeratx.com917-754-0207 Media Contact:Lissette L. SteeleVerge Scientific Communications for Kymera Therapeuticslsteele@vergescientific.com 202-930-4762
Unifrax, the leading manufacturer of high-performance specialty materials, today introduced its latest proprietary technology, SiFAB™ Silicon Fiber Anode Battery Technology by Unifrax. SiFAB, currently in advanced testing after years of research and development, has shown promising performance in multiple battery systems. This anode technology enables significantly higher energy density in lithium ion battery systems and has successfully been tested with incremental Si loadings of greater than 40 percent.
A consumer boom looks set to hit US high streets as "pent-up" spending is released into the economy. Questionmark, the online assessment provider, is calling on employers to ensure they have the staff they need, with the right skills, to take advantage of the post-Covid splurge.
Yahoo Finance